Developments in Viral Vector-Based Vaccines.
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.
Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan.
Takehiro
T
Ura
Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan.
Kenji
K
Okuda
Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan. mshimada@yokohama-cu.ac.jp.
Masaru
M
Shimada
CTL; MVA; adenovirus; vaccine; viral vector